

# Alzheimer's and Related Dementias Research: Tracking and Future Plans

---

## NAPA Advisory Council Meeting

Richard J. Hodes, M.D.  
Director  
National Institute on Aging

October 31, 2016

## IADRP Project Update: By the Numbers

---



Currently includes **35+** public, private and international funding organizations in **11** countries



Captures **7000+** unique basic, translational and health services research projects



Conducted by **4000+** researchers across **1000+** institutions



Represents **\$4.7 billion+** in funding

## Next Steps

---

- **CADRO** –
  - Collecting feedback for updating the CADRO.
- **New Federal Partners** –
  - The Federal Reporter website (<https://federalreporter.nih.gov/>) provides easier access to query research sponsored by other federal agencies.
  - NIA has recently identified small portfolios of AD and ADRD research supported by NASA, EPA and the Department of Agriculture.

## Next Steps, cont'd

---

- **AD Research Milestone Database** –
  - ADRD research milestones will be added to the database and to IADRP.
- **EU Joint Programme – Neurodegenerative Diseases (JPND)** –
  - NIH is participating in the upcoming EU mapping exercise that invites 20+ countries to submit their recently funded neurodegenerative research (notably AD and ADRD).
  - JPND has volunteered to ask participating countries if the results of this exercise can also be shared, coded and uploaded into IADRP.

### INTERNATIONAL ALZHEIMER'S DISEASE RESEARCH PORTFOLIO

The International Alzheimer's Disease Research Portfolio (IADRP) database brings together funded research supported by public and private organizations both in the US and abroad all categorized using the [Common Alzheimer's Disease Research Ontology or CADRO](#). Launched in 2010 as a joint collaboration between the [National Institute on Aging \(NIH\)](#) and the [Alzheimer's Association](#), IADRP enables users the ability to assess the portfolios of major organizations (currently 30+) for areas of overlap as well as areas of opportunities in which to collaborate and coordinate in a collective effort to advance AD research.

#### RESEARCH HIGHLIGHTS - NEW FUNDING ANNOUNCEMENTS

- [NIH Division of Neuroscience Funding Opportunities Database](#)
- [Alzheimer's Association - Research Grants Funding Page](#)
- [Alzheimer's Drug Discovery Foundation - Funding Opportunities Page](#)
- [Alzheimer's Research UK - Project Grants and Fellowships](#)
- [Alzheimer's Australia - Student and Early Career Investigators](#)
- [Alzheimer's Society of Canada - Young Investigator Awards](#)

#### HOW TO JOIN IADRP

The IADRP Project Team is currently seeking participation from public, private and international biomedical and public health organizations who fund Alzheimer's disease (AD) research. To find out more information about how your organization can contribute and help shape this effort, please contact [Charlene Liggins](mailto:ligginsc@mail.nih.gov) ([ligginsc@mail.nih.gov](mailto:ligginsc@mail.nih.gov)), [Nina Silverberg](mailto:silverbergn@mail.nih.gov) ([silverbergn@mail.nih.gov](mailto:silverbergn@mail.nih.gov)), or [Heather Snyder](mailto:hsnyder@alz.org) ([hsnyder@alz.org](mailto:hsnyder@alz.org)). [See [IADRP's Data Submission Process](#)]

#### IADRP QUICK SEARCH

Select CADRO Categories

Funding Organization Name

Funding Year

\_\_\_\_\_ or \_\_\_\_\_

Fulltext Search

Search Now

Visit IADRP @ <http://iadrp.nia.nih.gov/>

---

## Tracking Alzheimer's Disease Research Implementation Milestones

---

# AD Research Implementation Milestone Database

Enables users to search and track progress in funding research to address the 80+ AD Research Implementation Milestones

The screenshot shows the NIH National Institute on Aging website. The main heading is "ALZHEIMER'S DISEASE EDUCATION AND REFERRAL CENTER". Below that is the "Alzheimer's Disease Research Implementation Milestone Database" section. It includes a search bar with "Estimated Start", "AD Research Implementation Area", and "CADRO Category" dropdowns. Below the search bar is a table with columns: "Estimated Start", "AD Research Implementation Area", "CADRO Category", and "Milestone".

Estimated Start	AD Research Implementation Area	CADRO Category	Milestone
2016	Population Studies	D. Epidemiology	1.A: Create research programs aimed at extensive molecular endophenotyping of existing, at-risk cohorts from longitudinal studies that are genetically, epigenetically, or otherwise at risk.
2016	Population Studies	D. Epidemiology	1.B: Incorporate environmental context in human studies (e.g., epidemiological cohorts) and in clinical trials.

<https://www.nia.nih.gov/alzheimers/milestones>

# AD Research Implementation Milestone Database

Most milestones are linked to NIH funding opportunity announcements (FOAs), special, initiatives and related activities. Users will soon be able to link to specific projects supported under targeted FOAs as they are funded.

The screenshot shows the detail page for "Milestone 5.A". It includes a description: "Initiate first in human, phase I drug trials for therapeutic agents against at least 6 existing therapeutic targets. In addition to testing for safety, these trials will include assessment of target engagement." It also lists "Success Criteria", "Time Required" (2017 to 2023), "AD Research Implementation Area" (Drug Development - Existing Targets), and "CADRO Category" (C. Translational Research and Clinical Intervention). A blue box highlights the "Activities, Funding Initiatives, and Resources" section, which lists NIH PAR-14-089 and NIH PAR-16-365. Below that is the "Related Funded Projects (IADRP)" section, which lists "Category C, Translational Research and Clinical Interventions - 5, Early-stage Clinical Drug Development (Phase I and II Clinical)".

<https://www.nia.nih.gov/alzheimers/milestones>



## AD Research Implementation Milestone Database

**National Institute on Aging**  
Turning Discovery Into Health

Home Health and Aging Research and Funding Newsroom About NIA Contact Us

ALZHEIMER'S DISEASE EDUCATION AND REFERRAL CENTER

Home About Alzheimer's Find Help Research Federal Initiatives About ADEAR

### Milestone 5.A

Initiate first in human, phase I drug trials for therapeutic agents against at least 6 existing therapeutic targets. In addition to testing for safety, these trials will include assessment of target engagement.

**Success Criteria:**  
Completion of 12, Phase I drug trials for agents against 6 existing therapeutic targets.

**Time Required:**  
2017 to 2023

**AD Research Implementation Area:**  
Drug Development - Existing Targets

**CADRO Category:**  
C. Translational Research and Clinical Intervention

**Activities, Funding Initiatives, and Resources:**  
NIH PAR-14-089: Alzheimer's Disease Pilot Clinical Trials (R01)  
NIH PAR-16-365: Pilot Clinical Trials for the Spectrum of Alzheimer's Disease & Predicting Progression (R01)

**Related Funded Projects (IADRP):**  
[Category C, Translational Research and Clinical Interventions - 5, Early-stage Clinical Drug Development \(Phase I and II Clinical](#)

**Relevant Recommendation(s):**  
2012 Summit Recommendations: 3A, 3B, 3F, and 5E

Back

Common Alzheimer's Disease Research Ontology (CADRO) codes link milestones to related funded projects and other domestic and international funding organizations currently captured in IADRP

<https://www.nia.nih.gov/alzheimers/milestones>

## Tracking Progress – Ex.: Population Studies

**Milestone 1.D:** Develop state-of-the-art protocol for assessing dementia on large nationally representative samples that (a) includes racial/ethnic subsamples large enough to support disparities research and (b) is adaptable for use in comparable studies around the world [2015 AD Summit: 1B, 1.D, 3C, 3D, and 4B].

Success Criteria	Targeted Funding Opportunity Announcements (FOAs) and Special Initiatives (SIs)	Assigned CADRO Codes	Number of Funding Organizations (IADRP Partners)
Archive and share data for use by the research community.	<b>NIH PAR-15-349: Health Disparities and Alzheimer's Disease (R01)</b>	Category D. Epidemiology – 4. Multimodal Risk Factors	16
Update national estimates of the prevalence and incidence of dementia and cognitive impairment as well as address important questions about the epidemiology and population impact of dementia.	NIH PAR-15-350: Emerging Directions for Addressing Health Disparities in Alzheimer's Disease (R03)		
Repeat national estimates in 2021 to measure trend in dementia prevalence	NIH RFA-AG-15-015: Enhancing Cross-National Research within the Health and Retirement Study Family of Studies (R01)		
Support research projects comparing international differences to identify potential risk and protective factors.	NIH NOT-AG-14-022: NIA Population Study of Dementia in the Health and Retirement Study		
Support research on health disparities by racial/ethnic groups.			

From the milestone database, CADRO-coded milestones are linked to funded projects from multiple IADRP partners.

From IADRP, users can further filter results by

- Themes, such as **target population**
- Year
- Funding Organization

**IADRP** International Alzheimer's Disease Research Portfolio

Communicate Coordinate Collaborate

Home Advanced Database Search About IADRP About CADRO Reports and Publications Resources Help

**FILTER BY CADRO**

- Category D. Epidemiology
- 4. Multimodal Risk Factors
  - a. Hispanics (11)
  - b. African-Americans (26)
  - c. Japanese-Americans (13)
  - d. Multi-Racial/Cross-Cultural (73)
  - e. International (Israel, Sweden, China, India) (9)
  - f. Women (4)
  - g. Oldest Old (27)
  - h. Other (104)

**FILTER BY FISCAL YEAR (FY)**

- 2015 (35)
- 2014 (33)
- 2013 (34)
- 2012 (34)
- 2011 (31)
- 2010 (38)
- 2009 (46)
- 2008 (50)
- 2007 (3)

**FILTER BY FUNDING ORGANIZATION**

Visualize Data  
Displaying 1 - 20 of 304

Project Number	Title	FY	PI Full Name
TX-14	Characterization of Mexican Americans with Mild Cognitive Impairment		O'BRYAN, SID E
TX-15	Ethnicity effects on dementia-related anti-microbial biomarkers		Donald R. Royall, MD
R01AG028188	AGE RELATED COGNITIVE LOSS IN MUMBAI, INDIA	2010	PUROHIT, DUSHYANT P
ZIAAG000195	AGE-ASSOCIATED COGNITIVE CHANGES IN COMMUNITY DWELLING ADULTS	2010	ZONDERMAN, ALAN
U01AG006786	ALZHEIMER'S DISEASE PATIENT REGISTRY (ADPR)	2010	PETERSEN, RONALD C
U01AG006781	ALZHEIMER'S DISEASE PATIENT REGISTRY (ADPR)	2010	LARSON, ERIC B
5P41RR013642-13	BRAIN AGING IN JAPANESE-AMERICAN MEN	2010	LAUNER, LENORE
R01AG026096	CIND, RISK FACTORS FOR CONVERSION TO DEMENTIA	2010	UNVERZAGT, FREDERICK W.
R01AG021055	CLINICAL AND PATHOLOGICAL STUDIES IN THE OLDEST OLD	2010	KAWAS, CLAUDIA H.
R01AG012674	COGNITIVE ABILITIES OF AT-RISK ELDERLY FOR DEMENTIA	2010	BONDI, MARK W.
R01AG028419	EMOTIONAL AGING, PRESERVATION OF FUNCTION IN THE ELDERLY AND ALZHEIMER'S PATIENTS	2010	LARSEN, RANDALL S.
R01AG015553	EPIDEMIOLOGIC STUDY OF BRAIN VITAMIN E, DIET & AGE-RELATED NEUROLOGIC DISEASES	2010	MORRIS, MARTHA CLARE
R01AG033678	EPIDEMIOLOGIC STUDY OF IMPAIRED DECISION-MAKING IN PRECLINICAL ALZHEIMER'S DISEASE	2010	BOYLE, PATRICIA A.
R01AG017917	EPIDEMIOLOGIC STUDY OF NEURAL RESERVE AND NEUROBIOLOGY OF AGING	2010	BENNETT, DAVID ALAN
U01AG017155	EPIDEMIOLOGY OF AGING AND DEMENTIA - AUTOPSY RESEARCH	2010	WHITE, LON RAY
R01AG037212	EPIDEMIOLOGY OF BIOMARKERS OF RISK AND PROGRESSION IN LOAD	2010	MAYEUX, RICHARD
U01AG019349	EPIDEMIOLOGY OF BRAIN AGING IN THE VERY OLD	2010	WHITE, LON RAY
R01AG012975	EPIDEMIOLOGY OF FUNCTIONAL STATUS IN ELDERLY HISPANICS	2010	HAAN, MARY N.

### Example - NIH PAR-15-349: Health Disparities and Alzheimer's Disease (R01)

The milestone database will soon be linked directly to **NIH Reporter** to view specific projects as they are funded under targeted FOAs along with links and access to related **publications, patents and clinical trials**

U.S. Department of Health & Human Services

NIH Research Portfolio Online Reporting Tools (RePORT)

Search [ ]

HOME | ABOUT RePORT | FAQs | GLOSSARY | CONTACT US

QUICK LINKS RESEARCH ORGANIZATIONS WORKFORCE FUNDING REPORTS LINKS & DATA

Search Results

There were 6 results matching your search criteria. Click on the column header to sort the results.

Application Type	Act	Activity Code	Project	Admin IC	Serial No.	Year	Support Year	Supplements/Amendment	Contact PI/Project Leader	Organization	FY	Admin IC	Funding IC	FY Total Cost	Similar Projects
<input type="checkbox"/>	1	RE1	AG004988	01					CHEN, JIU-CHIUAN	UNIVERSITY OF SOUTHERN CALIFORNIA	2010	NIA	NIA	\$4,101,330	(i) (b)
<input type="checkbox"/>	1	R01	AG024089	01					GLEASON, CAREY E	UNIVERSITY OF WISCONSIN-MADISON	2010	NIA	NIA	\$704,903	(i) (b)
<input type="checkbox"/>	1	R01	AG023981	01					GLUCK, MARK A	RUTGERS THE STATE UNIV OF NJ NEWARK	2010	NIA	NIA	\$582,800	(i) (b)
<input type="checkbox"/>	1	R01	AG023972	01					HURD, MICHAEL D	RAND CORPORATION	2010	NIA	NIA	\$804,088	(i) (b)
<input type="checkbox"/>	1	RE1	AG004030	01					MANLY, JENNIFER JAE et al.	COLUMBIA UNIVERSITY HEALTH SCIENCES	2010	NIA	NIA	\$9,227,171	(i) (b)
<input type="checkbox"/>	1	R01	AG004033	01					O'BRYAN, SID E	UNIVERSITY OF NORTH TEXAS HLTH SCI CTR	2010	NIA	NIA	\$2,139,734	(i) (b)

Download Readers: PDF PPT PPTX


## Tracking Progress – Ex.: Drug Dev.: Existing Targets

Milestone 5.B: Initiate phase II (proof of concept) drug trials for agents against 3-6 currently known therapeutic targets. Of these at least 2 will be for targets involved in at-risk asymptomatic individuals (e.g. FAD or ApoE4 carriers, Down syndrome, amyloid positive, type II diabetes etc.) These trials will be designed to provide or confirm proof of mechanism and/or evidence of target engagement for the therapeutic agent being tested. [2012 AD Summit: 3A, 3B, 3F, and 5E]

Success Criteria	Targeted Funding Opportunity Announcements (FOAs) and Special Initiatives	Assigned CADRO Codes	Number of Funding Organizations (IADRP Partners)
Completion of 3-6 phase II drug trials for agents against currently known targets, providing conclusive evidence of therapeutic mechanism/target engagement.	<p>NIH Accelerating Medicines Partnership - AD Biomarkers Consortium</p> <p><b>NIH PAR-16-365: Pilot Clinical Trials for the Spectrum of Alzheimer's Disease &amp; Predicting Progression (R01)</b></p> <p>NIH PAR-14-089: Alzheimer's Disease Pilot Clinical Trials (R01)</p> <p>NIH RFA-AG-13-015: Alzheimer's Disease Prevention Trials (R01)</p> <p>NIH RFA-AG-13-001: Alzheimer's Disease Cooperative Study (U19)</p>	<p>Category C. Translational Research and Clinical Interventions - 5. Early-stage Clinical Drug Development (Phase I and II Clinical Trials)</p>	10

From IADRP, users can further filter results by

- Themes, such as **therapeutic target**
- Year
- Funding Organization



**IADRP** International Alzheimer's Disease Research Portfolio

Communicate  
Coordinate  
Collaborate

Home
Advanced Database Search
About IADRP
About CADRO
Reports and Publications
Resources
Help

**FILTER BY CADRO**

Category C. Translational Research and Clinical Interventions

5. Early stage Clinical Drug Development (Phase I and II Clinical Trials)

a. Amyloid (13)

b. Tau (5)

c. ApoE, Lipids, and Lipoprotein Receptors (4)

d. Neurotransmitter Receptors and Synaptic Plasticity (4)

e. Neurogenesis (3)

f. Inflammation (8)

g. Oxidative Stress (1)

j. Metabolism and Bioenergetics (31)

k. Vasculature (13)

l. Growth Factors and Hormones (17)

m. Epigenetic Regulators (3)

n. Multi-targets (4)

o. Unknown Target (2)

Show more

**FILTER BY FISCAL YEAR (FY)**

[Visualize Data](#)

Displaying 1 - 20 of 121

Export to XLS [CSV](#)

Project Number	Title	FY	PI Full Name
R01AG030048	<a href="#">A PHASE 2 TRIAL OF AAV-NGF GENE DELIVERY IN ALZHEIMER'S DISEASE</a>	2010	AISEN, PAUL S.
20101209	<a href="#">A Randomized, Double-Blind, Placebo-Controlled Phase 2 study to evaluate the effect of PBT2 (once daily for 52 weeks) on Abeta deposition in the brain of patients with Alzheimer's Disease</a>	2010	Angus, Dianne
U01AG010483	<a href="#">A TRIAL OF TTP488 TO SLOW THE RATE OF CLINICAL PROGRESSION OF PATIENTS WITH AD</a>	2010	GALASKO, DOUGLAS R
RC2AG056419	<a href="#">BRIDGING COGNITIVE AGING IN RODENTS TO MAN USING FMRI IN AMNESTIC MCI</a>	2010	GALLAGHER, MICHELA
P01AG020206	<a href="#">CLINICAL STUDIES OF NSAIDS AS Y-SECRETASE MODULATORS IN ALZHEIMER'S DISEASE</a>	2010	GALASKO, DOUGLAS R
R01AG033693	<a href="#">EFFECTS OF SIMVASTATIN ON CSF AD BIOMARKERS IN COGNITIVELY NORMAL SUBJECTS</a>	2010	LI, GAIL
R01AG022008	<a href="#">ESTROGEN USE IN PROTECTION FROM COGNITIVE DECLINE</a>	2010	RASGON, NATALIE L
20101203	<a href="#">Evaluation of MSDC-0160 in subjects with mild Alzheimer's disease</a>	2010	Colca, Jerry
R01AG030484	<a href="#">GHRH: CELLULAR INTEGRITY IN AGING AND MILD COGNITIVE IMPAIRMENT</a>	2010	FRIEDMAN, SETH DAVID
ZEN-10-173646	<a href="#">Intranasal Insulin Analogue Effects on CSF and Imaging Biomarkers in MCI</a>	2010	CRAFT, SUZANNE
R44AG029670	<a href="#">LEPTIN AS A THERAPY FOR ALZHEIMER'S DISEASE</a>	2010	TEZAPSIDIS, NIKOLAOS
R01AG026413	<a href="#">PILOT TRIAL OF METFORMIN IN AMNESTIC MCI</a>	2010	LUCHSINGER, JOSE A
20101202	<a href="#">Safety/Tolerability and Effects on Cognitive Impairment, Impaired Cerebral Cortical Metabolism and Oxidative Stress of R(+)-Pramipexole Administered to Subjects with Early Alzheimer's Disease</a>	2010	Bennett, James
R01AG031790	<a href="#">STATIN EFFECTS ON BETA-AMYLOID AND CEREBRAL PEREUSION IN ADULTS AT RISK FOR AD</a>	2010	CARLSSON, CYNTHIA M

7



Example -  
NIH PAR-16-365:  
Pilot Clinical Trials  
for the Spectrum of  
Alzheimer's Disease  
& Predicting  
Progression (R01)

Application Type	Act	Activity Code	Project	Admin IC	Serial No.	Year	Support Year	Supplement/Amendment	Contact PI	Project Leader	Organization	FY	Admin IC	Funding IC	FY Total Cost	Similar Projects
1	BF1	AG054175	Q1								CATALANO, SUSAN M	2010	NIA	NIA	\$2,410,669	<a href="#">[Link]</a>
1	R01	AG051628	Q1A1								DOODGE, HIROO; HAYAMA	2010	NIA	NIA	\$750,921	<a href="#">[Link]</a>
1	R01	AG050514	Q1A1								KOSSES, DIMITRIS N et al.	2010	NIA	NIA	\$772,824	<a href="#">[Link]</a>
1	R01	AG054130	Q1								MOGA, DANIELA; HANIGS et al.	2010	NIA	NIA	\$352,153	<a href="#">[Link]</a>
1	R01	AG051588	Q1A1								RICHARDS, KATHY; CLEPPER et al.	2010	NIA	NIA	\$807,079	<a href="#">[Link]</a>
1	R01	AG051545	Q1A1								SCHNAIDER BEER, MICHAEL et al.	2010	NIA	NIA	\$653,782	<a href="#">[Link]</a>
1	R01	AG051595	Q1A1								WINDISCH, MANFRED	2010	NIA	NIA	\$1,499,074	<a href="#">[Link]</a>

## Tracking Progress – Ex.: Care and Caregiver Support

Milestone 13.B: Launch research programs to develop and validate assessments of the psychological, financial, and physical health impact of caregiving. [2015 AD Summit 4B, 4D, 4H]

Success Criteria	Targeted Funding Opportunity Announcements (FOAs) and Special Initiatives	Assigned CADRO Codes	Number of Funding Organizations (IADRP Partners)
Identification and validation of assessments suitable for use in a range of research contexts including observational and interventional studies and large population-based surveys.	<b>NIH PAR-15-348: Research on Informal and Formal Caregiving for Alzheimer's Disease (R01)</b>	<b>Category E. Care, Support and Health Economics of Alzheimer's Disease - 3. Caregiver Support - e. Assessment and Metrics</b>	<b>15</b>
Identification and validation of at least one sensitive and robust measure for the detection of the earliest manifestations of caregiving burden and for monitoring its long-term consequences.	NIH PAR-15-351: Research on Informal and Formal Caregiving for Alzheimer's Disease (R21)		



From IADRP, users can further filter results by

- Themes, such as **type of caregiver research**
- Year
- Funding Organization

Example - NIH PAR-15-348: Research on Informal and Formal Caregiving for Alzheimer's Disease (R01)

## AD Research Implementation Milestone Database

- Database will soon include the ADRD Research Milestones (once approved)
- We encourage other organizations to also post (and link) their funding announcements and activities
  - Organizations can identify strategic areas in which to invest and collaborate
  - Researchers can assess funding opportunities across multiple funders

**Alzheimer's Disease Research Implementation Milestone Database**

This database is a web-based tool for tracking funding initiatives and activities developed by the NIH and other Alzheimer's disease (AD) funding organizations aimed at implementing the research milestones associated with the first goal of the National Plan to Address Alzheimer's: to treat and prevent Alzheimer's by 2025. The purpose of this new data resource is to facilitate strategic coordination and collaborations among funding organizations in order to maximize the impact of the collective investment in Alzheimer's research.

The milestones represent a research framework, detailing specific steps and success criteria for the NIH and other stakeholders towards the development of effective treatments for Alzheimer's. They were developed based on recommendations from the NIH AD Research Summits 2012 and 2015 put forward by over 120 leading academic and industry experts, innovators and public advocates. The milestones span the entire Alzheimer's research landscape including basic, translational, clinical and health services research and serve as the basis for the development of the NIH Alzheimer's Disease Bypass Budget.

The database can be searched based on research implementation areas and/or the Common Alzheimer's Disease Research Ontology (CADRO) categories. For each milestone, in addition to listing new funding initiative and programs, the database links to relevant projects funded by over 30 funding organizations, members of the International Alzheimer's Disease Research Portfolio (IADRP).

Estimated Start AD Research Implementation Area CADRO Category

Estimated Start AD Research Implementation Area CADRO Category Milestone

Estimated Start	AD Research Implementation Area	CADRO Category	Milestone
2016	Population Studies	D. Epidemiology	I.A: Create research programs aimed at extensive molecular endophenotyping of existing, at-risk cohorts from longitudinal studies that are genetically, epigenetically, or otherwise at risk...
2016	Population Studies	D. Epidemiology	I.B: Incorporate environmental context in human studies (e.g., epidemiological cohorts) and in clinical trials...

<https://www.nia.nih.gov/alzheimers/milestones>

## New AD Funding Opportunities

U.S. Department of Health and Human Services Alzheimer's Go4Life Español NIHSeniorHealth Publications

**NIH National Institute on Aging**  
Turning Discovery Into Health

Home Health and Aging Research and Funding Newsroom About NIA Contact Us

Home

**RESEARCH & FUNDING**

**Inside NIA: A Blog for Researchers**

**Preparing for a possible future: Advancing research into Alzheimer's disease**

Posted on October 12, 2016 by Richard Hodes, Director, National Institute on Aging. [See Richard Hodes' full profile.](#)

Our National Advisory Council on Aging meeting last month proved to be very exciting. We have received increased public interest, together with additional funding in recent years, to accelerate progress against Alzheimer's disease. These funds have allowed us to stretch our minds and extend our focus while all the time keeping our eyes on the goal of reducing the burden of Alzheimer's disease

**Inside NIA**  
A Blog for Researchers

**Subscribe**  
Get new posts by email.

Email

## **New Alzheimer's Concepts**

---

### **Resource Leveraging**

- Leveraging Existing Cohort Studies to Clarify Risk and Protective Factors for Alzheimer's disease and related dementias
- Validation of NIH Toolbox Instruments for Tracking and Diagnosis of MCI and early AD, and for Extension of Assessment in the Oldest Old

### **Caregiving and Clinical Care**

- Development of Socially Assistive Robots to Engage Persons with ADRD and their Caregivers
- Pragmatic Trials for Dementia Care in Long Term Services and Support (LTSS) Settings
- Improving Quality of Care and Quality of Life for Persons with Alzheimer's Disease and Related Dementia at the End of Life
- Tools for Clinical Care and Management of Alzheimer's disease and its comorbidities

## **New Alzheimer's Concepts**

---

### **Caregiving and Clinical Care Cont'd**

- Clarifying the relationship between delirium and Alzheimer's disease and related dementias
- NIA Small Business Opportunities to Advance Alzheimer's Disease Research
- Multimorbidity in Alzheimer's Disease Impacts Choice of Ancillary Treatments

### **Translation**

- Revision Applications to Enhance the Target and Biomarker Discovery Efforts of the AMP-AD and M<sup>2</sup>OVE-AD Consortia



## **New Alzheimer's Concepts**

---

### **Basic Research**

- Understanding the Effects of APOE2 on the Interaction between Aging and Alzheimer's Disease.
- Understanding the Impact of Sex Differences on the Phenotypes of AD Risk and Responsiveness to Therapy
- Role of Exosomes in Alzheimer's Disease
- Commonalities, and Interactions Between Neurodegenerative Diseases
- Human Cell Reprogramming for Functional Genetics of Alzheimer's Disease
- Brain lymphatic system in aging and Alzheimer's disease
- Mechanisms of Selective Neuronal Vulnerability in Alzheimer's Disease

## **New Alzheimer's Concepts**

---

### **Basic Research Cont'd**

- Systems biology approaches to Alzheimer's Disease using Non-Mammalian Models
- The role of aging metabolic changes in Alzheimer's disease (AD)
- The Role of Peripheral Proteostasis on Brain Aging and on Alzheimer's Disease
- Comparative Biology of Neurodegeneration
- Dynamic interactions between Peripheral Systems and the Brain in Aging and in Alzheimer's Disease
- Complex Biology of Resilience from Alzheimer's



## **New Alzheimer's Concepts**

---

### **Training**

- Alzheimer's Disease Research Revision Awards to Institutional Training Grants
- Institutional Training Programs to Advance Translational Research for Alzheimer's Disease and AD Related Dementias
- Research Career Enhancement Award to Advance Therapy Development for AD and Related Dementias

## **Ways to Stay Informed and Connected**

---

➤ Visit

**<https://www.nia.nih.gov/research/funding>**

to search all active NIA funding opportunities

➤ Subscribe to our blog to stay up to date with the latest from NIA


**<https://www.nia.nih.gov/research/blog>**

## Save the Dates!

AD Care and Services  
Research Summit  
**October 16-17, 2017**  
Bethesda, MD


Alzheimer's Disease  
Research Summit (III)  
**March 1-2, 2018**  
Bethesda, MD

**NIH** National Institute on Aging  
*Turning Discovery Into Health*



## Determinants of Disparities in Health and Life Expectancy

**FUNDAMENTAL FACTORS: Ethnicity, Gender, Age, Race, Identity\***



\*Gender, Ethnic, Racial and Sexual Identity

Adapted from: Lazarus & Folkman (1984); Pearlin (1989); Link and Phelan (1995); Jones (1997); Gerontimus (2000); Williams & Collins (2001); Adler (2010); McEwen (2010); Lopez-Otin (2013)